Successful Rechallenge with Imatinib in a Patient with Chronic Myeloid Leukemia Who Previously Experienced Imatinib Mesylate Induced Pneumonitis

Imatinib mesylate is a targeted therapy that acts by inhibiting tyrosine kinase of the bcr-abl fusion oncoprotein, which is specific to chronic myeloid leukemia (CML), and the c-transmembrane receptor, which is specific to gastrointestinal stromal tumors. Interstitial pneumonitis is a rare adverse e...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Go, Seong Woo, Kim, Boo Kyeong, Lee, Sung Hak, Kim, Tae-Jung, Huh, Joo Yeon, Lee, Jong Min, Hah, Jick Hwan, Kim, Dong Whi, Cho, Min Jung, Kim, Tae Wan, Kang, Ji Young
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: The Korean Academy of Tuberculosis and Respiratory Diseases 2013
Aiheet:
Case Report
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC3884114/
https://ncbi.nlm.nih.gov/pubmed/24416057
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4046/trd.2013.75.6.256
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia